Associated Papers
Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X et al.
Cell Biochemistry and Function, 2023
Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.
Lee SW et al.
Journal of Clinical Medicine, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E et al.
Genes, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
So-called "non-classic" ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors.
Zheng Q et al.
Human Pathology, 2018
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients.
Acquaviva G et al.
Scientific Reports, 2018
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation.
Udo E et al.
Diagnostic Pathology, 2017
Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device.
Yoon JH et al.
Plos One, 2017
Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung.
Kamata T et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X et al.
Histology and Histopathology, 2015
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C et al.
Neuro-oncology, 2013
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS et al.
Oncogene, 2012
Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
Leonardi R et al.
The Journal of Biological Chemistry, 2012
Cancer-associated isocitrate dehydrogenase mutations.
Yen KE et al.
The Oncologist, 2012
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Yen KE et al.
Oncogene, 2010
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y et al.
Biochemical and Biophysical Research Communications, 2010
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
Hemerly JP et al.
European Journal of Endocrinology, 2010
IDH mutations in glioma and acute myeloid leukemia.
Dang L et al.
Trends in Molecular Medicine, 2010
Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y et al.
Biochemical and Biophysical Research Communications, 2010
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Murugan AK et al.
Biochemical and Biophysical Research Communications, 2010